Translational Development Acquisition Corp.TDAC
Shareholder meeting
Jun 17, 2026
A meeting is scheduled. The deadline for electing to redeem usually falls two to seven days before it; this proxy did not state it in a form we would parse without guessing, so check the filing.
Cash in trust
$157M
$157,261,867
Trust per share
—
Redemption value
IPO
Dec 2024
—
Combination deadline
Jun 24, 2027
248 days remaining
Filings on record
79
Latest Oct 9, 2026
Business combination
- Target
- Not disclosed in an indexed filing
- Announced
- May 27, 2026
Overview
Translational Development Acquisition Corp. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001926599. It completed its initial public offering in Dec 2024 and listing on Nasdaq. Class A shares trade under the ticker TDAC, units under TDACU, warrants under TDACW on Nasdaq. The vehicle is sponsored by TDAC through TDAC Partners LLC. The mandate targets generalist. Definitive business-combination agreement signed, closing pending.
“we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business.”
Reading the filings
Arithmetic on what Translational Development Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Time on the clock
248 days to the Jun 24, 2027 deadline. The vehicle is early in its search window, and the deadline is not yet the binding constraint.
Extension history
Shareholders have already approved 1 extension. Each one opened a redemption window, so the public float and the trust are almost certainly smaller than at IPO, and each typically came with a sponsor contribution that lifts trust per share. A vehicle on its second or third extension is one where the sponsor is paying to keep the search alive.
Warrant coverage
Each unit carried one-half warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.
Underwriting
BTIG led the offering. It has been named on 79 SPAC IPOs, book-running 73 of them, and 52.8% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
From listing to the date Translational Development Acquisition Corp. must close a deal, extend again, or return the trust. The marker is today.
Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.
79 filings in all. 8 in the last three months, against a busiest month of 14.
Scores
Recomputed 2d agoThree readings of Translational Development Acquisition Corp., each an unweighted mean of the components shown beneath it, and each component a percentile against every live SPAC rather than an absolute we invented. They describe the setup, not the merit. How they are built
FOMO
ModerateHow much attention is this vehicle attracting right now?
38/100
- Filing activity46
2 in 30 days
- News coverage0
0 stories in 30 days
- Deal freshness67
announced 142 days ago
Attention is not quality. FOMO rises on news volume and on the market paying above trust, both of which have preceded plenty of disappointments.
Potential
ElevatedHow likely is this vehicle to complete a combination, and at what scale?
56/100
- Lead bank record23
38.5%
- Bank franchise69
68 SPAC mandates
- Trust scale46
$157M
- Stage85
definitive agreement signed
Potential is about execution, not about the target. It says nothing about whether the eventual deal is worth owning, because the target is usually unknown when the score is computed.
These are derived measures, not ratings of investment merit. They carry no view on the target, no price target and no recommendation, and a high score is not a reason to buy anything.
News on Translational Development Acquisition Corp.
Last 90 days- Translational Development Investor Alert: Kahn Swick & Foti, LLC Investigates Translational Development Acquisition Corp. - TDACNeutral
Press releasevia Google NewsBusiness Wire · 2mo ago
News sentiment
NeutralAcross 1 recent story, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.
SEC filing history
Free tier: filings older than 24 hours- 425
Business-combination communication
Accession 0001193125-26-417910
- 425
Business-combination communication
Accession 0001193125-26-401002
- 425
Business-combination communication
Accession 0001193125-26-389768
- 10-Q
Quarterly report
Accession 0001104659-26-097093
- SCHEDULE 13G
Beneficial ownership report (passive)
Accession 0001905106-26-000146
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001193125-26-351225
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0000886982-26-000457
- 425
Business-combination communication
Accession 0001193125-26-330513
- 425
Business-combination communication
Accession 0001193125-26-320984
- 425
Business-combination communication
Accession 0001104659-26-087089
- 8-K
Entry into a material definitive agreement
Items 1.01, 3.02, 9.01 · Accession 0001104659-26-087086
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001140361-26-028660
- 8-K
Other events
Items 8.01, 9.01 · Accession 0001104659-26-081579
- 425
Business-combination communication
Accession 0001193125-26-286758
- DEFA14A
Additional proxy soliciting material
Accession 0001104659-26-076687
- 425
Business-combination communication
Accession 0001104659-26-076686
- 8-K
Other events
Items 8.01, 9.01 · Accession 0001104659-26-076684
- 425
Business-combination communication
Accession 0001193125-26-278623
- 425
Business-combination communication
Accession 0001193125-26-276612
- 8-K
Entry into a material definitive agreement; Submission of matters to a vote of security holders
Items 1.01, 5.03, 5.07, 9.01 · Accession 0001104659-26-075471
- 425
Business-combination communication
Accession 0001193125-26-270239
- 8-K
Current report
Item 3.02 · Accession 0001104659-26-073428
- 425
Business-combination communication
Accession 0001193125-26-265584
- 425
Business-combination communication
Accession 0001193125-26-252878
- SCHEDULE 13G
Beneficial ownership report (passive)
Accession 0001193125-26-253165
- 4
Statement of changes in beneficial ownership
Accession 0001104659-26-068236
- DEFA14A
Additional proxy soliciting material
Accession 0001104659-26-067648
- DEF 14A
Definitive proxy statement
Accession 0001104659-26-067017
- 425
Business-combination communication
Accession 0001104659-26-066602
- 8-K
Entry into a material definitive agreement; Regulation FD disclosure
Items 1.01, 7.01, 9.01 · Accession 0001104659-26-066599
Pro
Track TDAC without the delay
Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.
- Filings live, no 24-hour delay
- One click through to the source document
- Deadline calendar out to 12 months
- CSV export, API and MCP access
Cancel any time. Billed monthly in USD.
Translational Development Acquisition Corp.: questions answered
What is Translational Development Acquisition Corp. (TDAC)?
Translational Development Acquisition Corp. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001926599. It completed its initial public offering in Dec 2024 and listing on Nasdaq. Class A shares trade under the ticker TDAC, units under TDACU, warrants under TDACW on Nasdaq. The vehicle is sponsored by TDAC through TDAC Partners LLC. The mandate targets generalist. Definitive business-combination agreement signed, closing pending.
How much does Translational Development Acquisition Corp. hold in trust?
Approximately $157,261,867, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must Translational Development Acquisition Corp. complete a merger?
By Jun 24, 2027, after 1 shareholder-approved extension. If no combination closes by then the sponsor must seek a further extension or wind the vehicle up and return the trust.
What happens if Translational Development Acquisition Corp. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in Translational Development Acquisition Corp., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
What tickers does Translational Development Acquisition Corp. trade under?
Class A shares trade as TDAC on Nasdaq, the units as TDACU, and the warrants as TDACW. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.
Is the trust value the same as the share price for Translational Development Acquisition Corp.?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
How much dilution do Translational Development Acquisition Corp.'s founder shares and warrants create?
Each unit also carried one-half warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.
Who sponsors Translational Development Acquisition Corp., and what is their track record?
TDAC Partners LLC is the sponsor entity, part of the TDAC franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Michael B. Hoffman.
Which banks underwrote the Translational Development Acquisition Corp. IPO?
BTIG. BTIG was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is Translational Development Acquisition Corp. tradeable, and where?
Yes. TDAC returned a live quote of $10.83 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.
Is Translational Development Acquisition Corp. a good investment?
That is not a question this site answers. Translational Development Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this Translational Development Acquisition Corp. data come from?
Filings Translational Development Acquisition Corp. submitted to the SEC under CIK 0001926599: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Oct 19, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
TDAC: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
BTIG in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Generalist SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All spacs with an announced deal
Definitive business-combination agreement signed, closing pending.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.